Factors associated to potentially inappropriate prescribing in older patients according to STOPP/START criteria: MoPIM multicentre cohort study

Marisa Baré, Marina Lleal, Sara Ortonobes, Maria Queralt Gorgas, Daniel Sevilla-Sánchez, Nuria Carballo, Elisabet De Jaime, Susana Herranz, MoPIM study group, Marisa Baré, Marina Lleal, Sara Ortonobes, Maria Queralt Gorgas, Daniel Sevilla-Sánchez, Nuria Carballo, Elisabet De Jaime, Susana Herranz, MoPIM study group

Abstract

Objectives: The objectives of the present analyses are to estimate the frequency of potentially inappropriate prescribing (PIP) at admission according to STOPP/START criteria version 2 in older patients hospitalised due to chronic disease exacerbation as well as to identify risk factors associated to the most frequent active principles as potentially inappropriate medications (PIMs).

Methods: A multicentre, prospective cohort study including older patients (≥65) hospitalized due to chronic disease exacerbation at the internal medicine or geriatric services of 5 hospitals in Spain between September 2016 and December 2018 was conducted. Demographic and clinical data was collected, and a medication review process using STOPP/START criteria version 2 was performed, considering both PIMs and potential prescribing omissions (PPOs). Primary outcome was defined as the presence of any most frequent principles as PIMs, and secondary outcomes were the frequency of any PIM and PPO. Descriptive and bivariate analyses were conducted on all outcomes and multilevel logistic regression analysis, stratified by participating centre, was performed on the primary outcome.

Results: A total of 740 patients were included (mean age 84.1, 53.2% females), 93.8% of them presenting polypharmacy, with a median of 10 chronic prescriptions. Among all, 603 (81.5%) patients presented at least one PIP, 542 (73.2%) any PIM and 263 (35.5%) any PPO. Drugs prescribed without an evidence-based clinical indication were the most frequent PIM (33.8% of patients); vitamin D supplement in older people who are housebound or experiencing falls or with osteopenia was the most frequent PPO (10.3%). The most frequent active principles as PIMs were proton pump inhibitors (PPIs) and benzodiazepines (BZDs), present in 345 (46.6%) patients. This outcome was found significantly associated with age, polypharmacy and essential tremor in an explanatory model with 71% AUC.

Conclusions: PIMs at admission are highly prevalent in these patients, especially those involving PPIs or BZDs, which affected almost half of the patients. Therefore, these drugs may be considered as the starting point for medication review and deprescription.

Trial registration number: NCT02830425.

Keywords: Potentially inappropriate prescribing; STOPP/START version 2; older patient; polypharmacy.

Conflict of interest statement

The authors declare that they have no competing interests.

© 2022. The Author(s).

Figures

Fig. 1
Fig. 1
% of patients presenting the following STOPP/START criteria. A: Potentially inappropriate medications (PIMs) found in most patients according to STOPP criteria (present in >2% of the patients). Subcategories of criterion A1 are shown in mild grey. B: Potential prescribing omissions (PPOs) found in most patients according to START criteria (present in >1% of the patients).

References

    1. Mangoni AA, Jarmuzewska EA. Incorporating pharmacokinetic data into personalised prescribing for older people: challenges and opportunities. Eur Geriatr Med. 2021;12:435–442. doi: 10.1007/s41999-020-00437-5.
    1. Hilmer SN, Gnjidic D. Prescribing for frail older people. Aust Prescr. 2017;40:174–178. doi: 10.18773/austprescr.2017.055.
    1. Fernández-Regueiro R, Fonseca-Aizpuru E, López-Colina G, Álvarez-Uría A, Rodríguez-Ávila E, Morís-De-La-Tassa J. Prescripción inadecuada y efectos adversos a medicamentos en pacientes de edad avanzada. Rev Clin Esp. 2011;221:400–406. doi: 10.1016/j.rce.2011.05.004.
    1. Hamilton H, Gallagher P, Ryan C, Byrne S, O’Mahony D. Potentially inappropriate medications defined by STOPP criteria and the risk of adverse drug events in older hospitalized patients. Arch Intern Med. 2011;171:1013–1019. doi: 10.1001/archinternmed.2011.215.
    1. Barry PJ, Gallagher P, Ryan C, O’mahony D. START (screening tool to alert doctors to the right treatment) an evidence-based screening tool to detect prescribing omissions in elderly patients. Age Ageing. 2007;36:632–638. doi: 10.1093/ageing/afm118.
    1. Cadogan CA, Ryan C, Hughes CM. Appropriate Polypharmacy and Medicine Safety: When Many is not Too Many. Drug Saf. 2016;39:109–116. doi: 10.1007/s40264-015-0378-5.
    1. Motter FR, Fritzen JS, Hilmer SN, Paniz ÉV, Paniz VMV. Potentially inappropriate medication in the elderly: a systematic review of validated explicit criteria. Eur J Clin Pharmacol. 2018;74:679–700. doi: 10.1007/s00228-018-2446-0.
    1. Gallagher P, O’Mahony D. STOPP (Screening Tool of Older Persons’ potentially inappropriate Prescriptions): Application to acutely ill elderly patients and comparison with Beers’ criteria. Age Ageing. 2008;37:673–679. doi: 10.1093/ageing/afn197.
    1. Gallagher P, Baeyens JP, Topinkova E, Madlova P, Cherubini A, Gasperini B, et al. Inter-rater reliability of STOPP (Screening Tool of Older Persons’ Prescriptions) and START (Screening Tool to Alert doctors to Right Treatment) criteria amongst physicians in six European countries. Age Ageing. 2009;38:603–606. doi: 10.1093/ageing/afp058.
    1. O’Mahony D, O’Sullivan D, Byrne S, O’Connor MN, Ryan C, Gallagher P. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing. 2015;44:213–218. doi: 10.1093/ageing/afu145.
    1. García-Gollarte F, Baleriola-Júlvez J, Ferrero-López I, Cruz-Jentoft AJ. Inappropriate drug prescription at nursing home admission. J Am Med Dir Assoc. 2012;13(83):e9–15. doi: 10.1016/j.jamda.2011.02.009.
    1. Sevilla-Sánchez D, Molist-Brunet N, Amblàs-Novellas J, Espaulella-Panicot J, Codina-Jané C. Potentially inappropriate medication at hospital admission in patients with palliative care needs. Int J Clin Pharm. 2017;39:1018–1030. doi: 10.1007/s11096-017-0518-3.
    1. Moriarty F, Bennett K, Cahir C, Kenny RA, Fahey T. Potentially inappropriate prescribing according to STOPP and START and adverse outcomes in community-dwelling older people: a prospective cohort study. Br J Clin Pharmacol. 2016;82:849–857. doi: 10.1111/bcp.12995.
    1. Prudence G, Maud C, Mélanie M, Bosson JL, Jean-Emmanuel B, Chanoine S, et al. Optimizing medication use in elderly people in primary care: Impact of STOPP criteria on inappropriate prescriptions. Arch Gerontol Geriatr. 2018;75:16–19. doi: 10.1016/j.archger.2017.10.022.
    1. Wauters M, Elseviers M, Vaes B, Degryse J, Dalleur O, Stichele R Vander, et al. Too many, too few, or too unsafe? Impact of inappropriate prescribing on mortality, and hospitalization in a cohort of community-dwelling oldest old. Br J Clin Pharmacol Br J Clin Pharmacol. 2016;82:1382. doi:10.1111/bcp.13055.
    1. Sevilla-Sanchez D, Molist-Brunet N, Amblàs-Novellas J, Roura-Poch P, Espaulella-Panicot J, Codina-Jané C. Adverse drug events in patients with advanced chronic conditions who have a prognosis of limited life expectancy at hospital admission. Eur J Clin Pharmacol. 2017;73:79–89. doi: 10.1007/s00228-016-2136-8.
    1. OD Riordan, Aubert CE, Walsh KA, Van Dorland A, Rodondi N, Du Puy RS, et al. Prevalence of potentially inappropriate prescribing in a subpopulation of older European clinical trial participants: A cross-sectional study. BMJ Open. 2018;8:19003. doi:10.1136/bmjopen-2017-019003.
    1. Baré M, Herranz S, Jordana R, Gorgas MQ, Ortonobes S, Sevilla D, et al. Multimorbidity patterns in chronic older patients, potentially inappropriate prescribing and adverse drug reactions: protocol of the multicentre prospective cohort study MoPIM. BMJ Open. 2020;10:e033322. doi: 10.1136/bmjopen-2019-033322.
    1. Mahoney F, Barthel D. Functional evaluation: the Barthel Index. Md State Med J. 1965;14:61–65.
    1. Charlson ME, Peter P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis. 1987;40:373–383. doi: 10.1016/0021-9681(87)90171-8.
    1. Barrio I, Arostegui I, Rodríguez-Álvarez MX, Quintana JM. A new approach to categorising continuous variables in prediction models: Proposal and validation. Stat Methods Med Res. 2017;26:2586–2602. doi: 10.1177/0962280215601873.
    1. Quan H, Li B, Couris CM, Fushimi K, Graham P, Hider P, et al. Updating and validating the charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173:676–682. doi: 10.1093/aje/kwq433.
    1. Baztan J, Perez del Molino J, Alarcon T, San Cristobal E, Izquierdo G, Manzarbeitia J. Indice de Barthel: instrumento válido para la valoración funcional de pacientes con enfermedad cerebrovascular. Rev Esp Geriatr Gerontol. 1993;28:32–40.
    1. Baré M, Herranz S, Roso-Llorach A, Jordana R, Violán C, Lleal M, et al. Multimorbidity patterns of chronic conditions and geriatric syndromes in older patients from the MoPIM multicentre cohort study. BMJ Open. 2021;11:49334. doi: 10.1136/bmjopen-2021-049334.
    1. Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017;17:230. doi: 10.1186/s12877-017-0621-2.
    1. Hernández-Rodríguez MÁ, Sempere-Verdú E, Vicens-Caldentey C, González-Rubio F, Miguel-García F, Palop-Larrea V, et al. Evolution of polypharmacy in a spanish population (2005-2015): A database study. Pharmacoepidemiol Drug Saf. 2020;29:433–443. doi: 10.1002/pds.4956.
    1. Thomas RE, Thomas BC. A Systematic Review of Studies of the STOPP/START 2015 and American Geriatric Society Beers 2015 Criteria in Patients ≥ 65 Years. Curr Aging Sci. 2019;12:121–154. doi: 10.2174/1874609812666190516093742.
    1. Monteiro C, Canário C, Ribeiro MÂ, Duarte AP, Alves G. Medication Evaluation in Portuguese Elderly Patients According to Beers, STOPP/START Criteria and EU(7)-PIM List – An Exploratory Study. Patient Prefer Adherence. 2020;14:795–802. doi: 10.2147/PPA.S247013.
    1. Pardo-Cabello AJ, Manzano-Gamero V, Zamora-Pasadas M, Gutiérrez-Cabello F, Esteva-Fernández D, De Dios J, et al. Potentially inappropriate prescribing according to STOPP-2 criteria among patients discharged from Internal Medicine: prevalence, involved drugs and economic cost. Arch Gerontol Geriatr. 2017;74:150–154. doi: 10.1016/j.archger.2017.10.009.
    1. Fernández Regueiro R, Estrada Menéndez C, Morís de la Tassa J. Impact of an intervention program to improve potentially inappropriate prescription in hospitalized elderly patients. Rev Clin Esp. 2019;219:375–385. doi: 10.1016/j.rce.2018.12.012.
    1. Bo M, Gibello M, Brunetti E, Boietti E, Sappa M, Falcone Y, et al. Prevalence and predictors of inappropriate prescribing according to the Screening Tool of Older People’s Prescriptions and Screening Tool to Alert to Right Treatment version 2 criteria in older patients discharged from geriatric and internal medicine ward. Geriatr Gerontol Int. 2019;19:5–11. doi: 10.1111/ggi.13542.
    1. Ryan C, O’mahony D, Kennedy J, Weedle P, Cottrell E, Heffernan M, et al. Potentially inappropriate prescribing in older residents in irish nursing homes. Age Ageing. 2013;42:116–120.
    1. Mucalo I, Hadžiabdić MO, Brajković A, Lukić S, Marić P, Marinović I, et al. Potentially inappropriate medicines in elderly hospitalised patients according to the EU(7)-PIM list, STOPP version 2 criteria and comprehensive protocol. Eur J Clin Pharmacol. 2017;73:991–999. doi: 10.1007/s00228-017-2246-y.
    1. AEMPS - Agencia Española de Medicamentos y Productos Sanitarios. Utilización de medicamentos antiulcerosos en España durante el periodo 2000-2012 [Use of anti-ulcer drugs in Spain during the period 2000-2012]. 2014. moz-extension://b209cb6f-a896-47b9-b341-9de6d5f34601/enhanced-reader.html?openApp&pdf=https%3A%2F%%2FmedicamentosUsoHumano%2Fobservatorio%2Fdocs%2Fantiulcerosos.pdf.
    1. Thong BKS, Ima-Nirwana S, Chin KY. Proton pump inhibitors and fracture risk: A review of current evidence and mechanisms involved. Int J Environ Res Public Health. 2019;16:1571. doi: 10.3390/ijerph16091571.
    1. Kieboom BCT, Kiefte-De Jong JC, Eijgelsheim M, Franco OH, Kuipers EJ, Hofman A, et al. Proton Pump Inhibitors and Hypomagnesemia in the General Population: A Population-Based Cohort Study. Am J Kidney Dis. 2015;66:775–782. doi: 10.1053/j.ajkd.2015.05.012.
    1. Jaynes M, Kumar AB. The risks of long-term use of proton pump inhibitors: a critical review. Ther Adv Drug Saf. 2018;10:2042098618809927. doi: 10.1177/2042098618809927.
    1. Lazarus B, Chen Y, Wilson FP, Sang Y, Chang AR, Coresh J, et al. Proton Pump Inhibitor Use and Risk of Chronic Kidney Disease. JAMA Intern Med. 2016;176:238–246. doi: 10.1001/jamainternmed.2015.7193.
    1. Al-Aly Z, Maddukuri G, Xie Y. Proton Pump Inhibitors and the Kidney: Implications of Current Evidence for Clinical Practice and When and How to Deprescribe. Am J Kidney Dis. 2020;75:497–507. doi: 10.1053/j.ajkd.2019.07.012.
    1. D’Silva KM, Mehta R, Mitchell M, Lee TC, Singhal V, Wilson MG, et al. Proton pump inhibitor use and risk for recurrent Clostridioides difficile infection: a systematic review and meta-analysis. Clin Microbiol Infect. 2021;27:697–703. doi: 10.1016/j.cmi.2021.01.008.
    1. Inghammar M, Svanström H, Voldstedlund M, Melbye M, Hviid A, Mølbak K, et al. Proton-Pump Inhibitor Use and the Risk of Community-Associated Clostridium difficile Infection. Clin Infect Dis. 2021;72:e1084–e1089. doi: 10.1093/cid/ciaa1857.
    1. Zhang Y, Liang M, Sun C, Song EJ, Cheng C, Shi T, et al. Proton pump inhibitors use and dementia risk: a meta-analysis of cohort studies. Eur J Clin Pharmacol. 2020;76:139–147. doi: 10.1007/s00228-019-02753-7.
    1. Torres-Bondia F, Dakterzada F, Galván L, Buti M, Besanson G, Gill E, et al. Proton pump inhibitors and the risk of Alzheimer’s disease and non-Alzheimer’s dementias. Sci Rep. 2020;10:1–9. doi: 10.1038/s41598-020-78199-0.
    1. Nguyen PA, Islam M, Galvin CJ, Chang C-C, An SY, Yang H-C, et al. Meta-analysis of proton pump inhibitors induced risk of community-acquired pneumonia. Int J Qual Heal Care. 2020;32:292–299. doi: 10.1093/intqhc/mzaa041.
    1. Diane Zheng D, Loewenstein DA, Christ SL, Feaster DJ, Lam BL, McCollister KE, et al. Multimorbidity patterns and their relationship to mortality in the US older adult population. PLoS One. 2021;16:e0245053. doi: 10.1371/journal.pone.0245053.
    1. Li GF, An XX, Yu Y, Jiao LR, Canarutto D, Yu G, et al. Do proton pump inhibitors influence SARS-CoV-2 related outcomes? A meta-analysis. Gut. 2020;70:1806–1808.
    1. Kow CS, Hasan SS. Use of proton pump inhibitors and risk of adverse clinical outcomes from COVID-19: a meta-analysis. J Intern Med. 2021;289:125–128. doi: 10.1111/joim.13183.
    1. Torres-Bondia F, De Batlle J, Galván L, Buti M, Barbé F, Pinõl-Ripoll G. Trends in the consumption rates of benzodiazepines and benzodiazepine-related drugs in the health region of Lleida from 2002 to 2015. BMC Public Health. 2020;20:1–9. doi: 10.1186/s12889-020-08984-z.
    1. AEMPS - Agencia Española de Medicamentos y Productos Sanitarios. Utilización de medicamentos ansiolíticos e hipnóticos en España durante el periodo 2010-2019 [Use of anxiolytic and hypnotic drugs in Spain during the period 2010-2019]. .
    1. Gerlach LB, Wiechers IR, Maust DT. Prescription Benzodiazepine Use among Older Adults: A Critical Review. Harv Rev Psychiatry. 2018;26:264–273. doi: 10.1097/HRP.0000000000000190.
    1. Markota M, Rummans TA, Bostwick JM, Lapid MI. Benzodiazepine Use in Older Adults: Dangers, Management, and Alternative Therapies. Mayo Clin Proc. 2016;91:1632–1639. doi: 10.1016/j.mayocp.2016.07.024.
    1. Counter D, Millar JWT, McLay JS. Hospital readmissions, mortality and potentially inappropriate prescribing: a retrospective study of older adults discharged from hospital. Br J Clin Pharmacol. 2018;84:1757–1763. doi: 10.1111/bcp.13607.
    1. Hudhra K, Beçi E, Petrela E, Xhafaj D, García-Caballos M, Bueno-Cavanillas A. Prevalence and factors associated with potentially inappropriate prescriptions among older patients at hospital discharge. J Eval Clin Pract. 2016;22:707–713. doi: 10.1111/jep.12521.
    1. Hedera P, Cibulčík F, Davis T, l. Pharmacotherapy of Essential Tremor. J Cent Nerv Dis. 2013;5:43–55.
    1. Mori ALPM, Carvalho RC, Aguiar PM, de Lima MGF, Rossi M da SPN, Carrillo JFS, et al. Potentially inappropriate prescribing and associated factors in elderly patients at hospital discharge in Brazil: a cross-sectional study. Int J Clin Pharm. 2017;39:386–393. doi:10.1007/s11096-017-0433-7.
    1. Kara Ö, Arık G, Kızılarslanoglu MC, Kılıc MK, Varan HD, Sümer F, et al. Potentially inappropriate prescribing according to the STOPP/START criteria for older adults. Aging Clin Exp Res. 2016;28:761–768. doi: 10.1007/s40520-015-0475-4.
    1. Baruth JM, Gentry MT, Rummans TA, Miller DM, Burton MC. Polypharmacy in older adults: the role of the multidisciplinary team. Hosp Pract. 1995;2020(48):56–62. doi: 10.1080/21548331.2019.1706995.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅